Vestmark Advisory Solutions Inc. Sells 49,744 Shares of Koninklijke Philips N.V. $PHG

Vestmark Advisory Solutions Inc. decreased its position in shares of Koninklijke Philips N.V. (NYSE:PHG) by 39.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 76,232 shares of the technology company’s stock after selling 49,744 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Koninklijke Philips were worth $1,828,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cetera Trust Company N.A boosted its position in shares of Koninklijke Philips by 4.9% during the second quarter. Cetera Trust Company N.A now owns 12,173 shares of the technology company’s stock valued at $292,000 after purchasing an additional 564 shares in the last quarter. Bridgewater Advisors Inc. purchased a new position in Koninklijke Philips during the second quarter valued at $189,000. Atria Investments Inc boosted its holdings in shares of Koninklijke Philips by 9.1% during the 2nd quarter. Atria Investments Inc now owns 20,517 shares of the technology company’s stock valued at $492,000 after buying an additional 1,707 shares in the last quarter. Investment Management Associates Inc. ADV bought a new stake in shares of Koninklijke Philips during the 2nd quarter valued at $12,122,000. Finally, Hantz Financial Services Inc. grew its position in shares of Koninklijke Philips by 7.3% in the 2nd quarter. Hantz Financial Services Inc. now owns 72,798 shares of the technology company’s stock worth $1,746,000 after buying an additional 4,937 shares during the period. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Stock Down 0.3%

NYSE:PHG opened at $28.16 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.86 and a current ratio of 1.32. The firm has a market cap of $27.11 billion, a P/E ratio of 140.80, a P/E/G ratio of 0.76 and a beta of 0.82. Koninklijke Philips N.V. has a fifty-two week low of $21.48 and a fifty-two week high of $29.28. The firm has a 50-day simple moving average of $27.87 and a two-hundred day simple moving average of $25.89.

Koninklijke Philips (NYSE:PHG) last issued its earnings results on Tuesday, November 4th. The technology company reported $0.37 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.37. The firm had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.30 billion. Koninklijke Philips had a net margin of 1.07% and a return on equity of 12.14%. Analysts predict that Koninklijke Philips N.V. will post 1.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PHG has been the subject of a number of recent research reports. Weiss Ratings raised shares of Koninklijke Philips from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Wall Street Zen lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.